近期明德生物（002932）发布2024年年报，证券之星财报模型分析如下： 从单季度数据来看，第四季度营业总收入为1.24亿元，同比上升0.68%；归母净利润为-641.88万元，同 比上升90.88%；扣非净利润为-1.01亿元，同比上升40.45%。虽然第四季度营收略有增长，但扣非净利 润仍为负值，且全年整体表现不佳。 费用与利润率 经营概况 明德生物发布的2024年年报显示，公司全年营业总收入为3.5亿元，同比下降53.3%。归母净利润为 7451.96万元，同比下降0.54%。扣非净利润为-1.4亿元，同比下降12.74%。尽管归母净利润降幅较小， 但扣非净利润的大幅下滑表明公司主营业务盈利能力减弱。 单季度表现 总体来看，明德生物2024年的财务表现不尽如人意，主营收入和利润均出现不同程度的下滑，费用占比 上升明显。公司需进一步优化成本控制，提升主营业务盈利能力，以应对未来的市场挑战。 货币资金：4.94亿元，同比下降51.37% 应收账款：7.64亿元，同比下降36.79% 有息负债：729.63万元，同比下降76.39% 每股净资产：25.06元，同比下降3.31% 每股经营性现金流：-0.37 ...

证券代码：301060 证券简称：兰卫医学 公告编号：2025-004 一、重要提示 本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投资者 应当到证监会指定媒体仔细阅读年度报告全文。 所有董事均已出席了审议本报告的董事会会议。 容诚会计师事务所（特殊普通合伙）对本年度公司财务报告的审计意见为：标准的无保留意见。 本报告期会计师事务所变更情况：公司本年度会计师事务所由变更为容诚会计师事务所（特殊普通合 伙）。 非标准审计意见提示 □适用 √不适用 公司上市时未盈利且目前未实现盈利 □适用 √不适用 董事会审议的报告期利润分配预案或公积金转增股本预案 √适用 □不适用 公司经本次董事会审议通过的利润分配预案为：以公司总股本400,517,000股剔除公司回购专用账户股份 数量后的总股本398,520,900股为基数，向全体股东每10股派发现金红利2元（含税），送红股0股（含 税），以资本公积金向全体股东每10股转增0股。 董事会决议通过的本报告期优先股利润分配预案 □适用 √不适用 二、公司基本情况 1、公司简介 ■ 2、报告期主要业务或产品简介 公司是一家为医学诊断行业提供 ...

亚辉龙 20250427 摘要 • 亚辉龙 2024 年总营收 17.72 亿元，同比增长 26.13%，但 2025 年一季 度营收同比下降 3.13%至 4.18 亿元。非新冠自产业务 2024 年营收 16.72 亿元，同比增长 24.11%，2025 年一季度增长 1.09%至 3.45 亿 元。海外非新冠自产业务增长迅速，2024 年增长 64.78%，2025 年一季 度增长 46.53%，占比提升。 • 2024 年主营业务毛利率为 65.15%，同比增加 8.58 个百分点，主要得益 于非新冠自产业务收入占比提升。但 2025 年一季度毛利率下降至 58.87%，同比下降 2.9 个百分点，主要由于高毛利项目销售减少及设备 销售比例提升。化学发光试剂业务毛利率也出现下滑。 • 亚辉龙 2024 年销售费用增加 9.94%，研发费用增长 6.16%，研发费用 率达 16.74%。2025 年一季度销售费用大幅增长 52%，管理费用增长 176%，但研发费用同比下降 20.78%，整体费用控制良好。 • 2024 年全自动化学发光免疫分析仪收入 15.22 亿元，同比增长 30.27%，海外地区增 ...

掘金·年报一季报业绩解读 20250427 摘要 • 福斯特：2025 年胶膜海外产能放量，海外毛利率约 20%高于境内，盈利 优势有望扩大。电子材料业务增长及毛利率提升，显著增厚业绩。预计 2025-2027 年净利润分别为 17.4 亿元、20.2 亿元和 23.6 亿元。 • 联泓新科：2025 年一季度营收 15.4 亿元，同比增长 3%，归母净利润 0.7 亿元，同比增长 39%，主要受益于 EVA 产品销量大增和成本下降。 预计二季度 EVA 价格和盈利有望继续修复，多条新产线陆续放量。 • 联泓新科：计划在 2025-2026 年陆续投产多条新的生产线，包括 20 万吨 EVA 装置、10 万吨 POE 装置以及锂电添加剂 VC、Pae 等 PVC 装置。略 上调 2025-2027 年的盈利预测至 3.02 亿、5.96 亿和 7.38 亿元。 • 阳光电源：2024 年度归母净利润 110 亿元，同比增长 17%，2025 年一 季度利润 38 亿元，同比大增 83%。2024 年度经营性现金流 121 亿元， 同比增长 73%。预计 2025-2027 年归母净利润分别为 144 亿、17 ...

Core Viewpoint - Ruiang Gene's stock closed at 20.89 yuan, up 2.50%, with a market-to-book ratio of 1.28 and a total market value of 1.167 billion yuan [1] Company Overview - Ruiang Gene specializes in the research, production, sales, and scientific services of in vitro diagnostic products, with key products including leukemia-related fusion gene testing kits and various gene mutation testing kits [1] - As of December 31, 2024, the company holds 114 medical device products approved or registered by the National Medical Products Administration, including 31 Class III medical device registration products [1] Financial Performance - In the first quarter of 2025, the company reported operating revenue of 54.738 million yuan, a year-on-year decrease of 14.72%, while net profit reached 3.355 million yuan, a significant increase of 529.26%, with a sales gross margin of 71.00% [2] - The company's price-to-earnings (P/E) ratio (TTM) is -90.15, and the price-to-book (P/B) ratio is 1.28, with a total market value of 1.167 billion yuan [2]

每经记者 王琳 每经编辑 马子卿 4月24日晚间，明德生物（SZ002932，股价18.09元，市值42.06亿元）发布2024年年报，公司在2024年 实现营业收入3.50亿元，同比下降53.30%，其扣非净利润则连续第二年录得亏损。这样的业绩也使得明 德生物与"扣非净利润为负且营业收入不足3亿元"的"退市预警线"距离被大幅拉近。 值得一提的是，明德生物在2024年末的可分配利润甚至超过其总市值（按4月24日收盘价计算）。在这 样的情况下，明德生物再次回归高分红，宣布拟向全体股东每10股派发现金红利12元（含税），分红金 额达2.63亿元。以4月24日收盘价计算，其股息率高达近7%。 年报显示，明德生物在2024年实现营业收入和归母净利润分别为3.5亿元和7452万元，同比分别下降 53%和0.54%。此外，公司扣非净利润则录得亏损1.4亿元，连续第二年亏损，亏损额较2023年也有所扩 大。 分季度来看，明德生物在2024年第四季度的营业收入为1.24亿元，较2023年同期略有增长，其在2024年 第四季度的归母净利润和扣非净利润也较上年同期均明显减亏。 明德生物表示，公司2024年度营业收入大幅下降以及扣 ...

金十数据4月25日讯，英诺特公告，公司拟作为有限合伙人以自有资金认缴出资人民币19,900万元，与 嘉兴君重资产管理有限公司共同出资设立嘉兴英诺特体外诊断产业投资并购合伙企业（有限合伙）。该 基金投资领域为生物医药领域的非上市企业，包括但不限于体外诊断、生命科学等领域的成长性企业。 英诺特出资占比99.50%。 英诺特：拟出资1.99亿元参与设立产业基金 ...

Core Viewpoint - The company demonstrated strong operational resilience in its 2024 annual report, achieving a revenue of 2.012 billion yuan and a net profit of 302 million yuan, with a significant year-on-year growth in its self-owned business segment [2] Group 1: Financial Performance - The company reported a revenue of 2.012 billion yuan for 2024, with a net profit attributable to shareholders of 302 million yuan and a non-recurring net profit of 287 million yuan [2] - Revenue from the self-owned business segment reached 1.672 billion yuan, marking a year-on-year increase of 26.13% [2] Group 2: R&D and Technological Advancements - The company invested 338 million yuan in R&D for 2024, representing a year-on-year increase of 3.84% and accounting for 16.80% of total revenue [2] - The company has established a humanized antibody technology platform and integrated AI into the development of bioactive raw materials [3] Group 3: Product Development and Market Expansion - The company added 15 new chemical luminescence testing reagent projects, bringing the total to 178 registered projects by the end of the reporting period [3] - In the first quarter of 2025, the company added 6 more projects, increasing the total to 184 [3] - The company achieved a revenue of 250 million yuan from overseas self-owned business, reflecting a year-on-year growth of 64.78% [3] Group 4: Automation and Smart Solutions - The company developed the iTLA Max laboratory automation system, which integrates AI technology and can process up to 1,200 sample tubes per hour [3] - The automation system connects various instruments and utilizes intelligent robots for automatic supply addition [3] Group 5: International Market Performance - In the first quarter of 2025, the company added 283 new installations overseas, representing a year-on-year increase of 92.52% [3] - The overseas market generated a revenue of 52.3813 million yuan from chemical luminescence business, showing a year-on-year growth of 56.31% [3]

导读： 丹纳赫发布一季度财报，营收57.41亿美元，同比小幅下降0.95%，核心业务收入持平超预期。此外，关于关税问题，丹纳赫回应相信通过供应链重组和本 土化布局，能够很大程度抵消当前关税影响。 特别提示 微信公众号机制调整，请点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 关税政策的影响持续发酵。生命科学和诊断领域的巨头丹纳赫发布一季度财报，谈及了如何应对关税影响。 在当前形势下，加速供应链重组与 本土化布局，已然成为企业应对潜在的新政风险的必要之举。 先看财报，丹纳赫2 0 2 5年Q1营收5 7 . 4 1亿美元，同比小幅下降0 . 9 5%。 | | Three-Month Period Ended | | | --- | --- | --- | | | March 28, 2025 March 29, 2024 | | | Sales (GAAP) | | | | Biotechnology | 5 1,612 $ | 1,524 | | Life Sciences | 1,680 | 1,745 | | Diagnostics | 2.449 | 2, ...

Core Viewpoint - The company, Suzhou Nanwei Technology Co., Ltd., focuses on the research, production, and sales of high-performance nano-microsphere materials, aiming to become a leading brand in the microsphere industry and break the long-standing foreign monopoly in this field [7][28]. Company Overview - The company specializes in high-performance nano-microsphere materials for applications in biomedicine, flat panel displays, analytical testing, and in vitro diagnostics [7][9]. - It has developed proprietary technologies for precise control over microsphere size, morphology, and surface properties, enabling customized production [8][28]. Business Model - The company operates a complete procurement, production, sales, and R&D system, adapting its business model based on market conditions and customer needs [10][11]. - It employs a direct sales model, engaging with clients from the early stages of product development to provide tailored purification solutions [14][31]. Industry Situation - The biopharmaceutical separation and purification industry is critical, with chromatography technology being the primary method for achieving high purity and yield in biopharmaceutical production [17][20]. - The global biopharmaceutical market is projected to grow significantly, with a compound annual growth rate (CAGR) of 12.20% from 2020 to 2025, driven by advancements in monoclonal antibody products [18][19]. Market Dynamics - The Chinese biopharmaceutical market is expected to reach RMB 811.6 billion by 2025, with a CAGR of 18.6% from 2020 to 2025, indicating strong growth potential [19]. - The demand for domestic high-performance separation and purification materials is increasing due to rising production costs and the need for stable supply chains amid international uncertainties [30][32]. Technological Development - The company has established a comprehensive technology development and industrialization system for microsphere precision preparation, making it one of the few capable of large-scale production of both inorganic and organic high-performance nano-microspheres [28]. - Recent acquisitions, such as that of Fuli Instruments, enhance the company's capabilities in providing integrated analytical solutions [29]. Financial Overview - The company plans to distribute a cash dividend of RMB 0.63 per share, with total cash dividends and share repurchase amounting to RMB 86.24 million, representing 104.10% of the net profit attributable to shareholders for 2024 [4][5].